StemSpine® Peer Reviewed Publication on 2 Year Pilot Study Results


Creative Medical Technology Holdings, Inc.


Creative Medical Technology Holdings, Inc. (CELZ) is a leading commercial stage biotechnology company committed to improving patient lives via a regenerative approach to immunology, urology, neurology, and orthopedics. CELZ is supported by a leadership team with extensive experience, a large scientifically based patent portfolio and a well defined business strategy.

The Company is advancing two unique platforms – Supercharged Autologous Immunotherapy and Rapid Autologous Stem Cell Platform across multiple indications. ImmCelz is our first Supercharged Autologous Immunotherapy platform. ImmCelz platform utilizes secreted factors from universal donor cells to reprogram the patient’s own immune cells. On the other hand, Rapid Autologous Stem Cell Platform involves harvesting stem cells from patient’s bone marrow and injecting it back into the patient in a short outpatient procedure.

Intellectual Property

CELZ has developed/acquired a robust intellectual property (IP) portfolio related to the utilization of stem cells to improve patient lives in the areas of immunology, urology, neurology, and orthopedics.

This IP portfolio positions us at the forefront of the regenerative medicine industry (set to grow to $79Bn 2026). We plan to commercialize these products on our own and in collaboration with strategic partners.

Timothy Warbington

Chief Executive Officer

Donald Dickerson

Chief Financial Officer

Courtney Bartlett

Director of Clinical Development

Timothy Warbington

Donald Dickerson

Bruce S. Urdang

Susan Snow

Mike Finger



We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.


For inquiries, please contact the company:

Contact Us